{
  "label": "clinical_signal_03_ep_020",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:472185977317432aae742f83dfcc44d6a62abe6d05f781b83676a95d2486aa77",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:55:10.145269",
  "content": "## 2024-07-15 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 216\n- Active: 206\n- Screen Failures Cumulative: 45\n- Withdrawals Cumulative: 10\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 22\n- Site 01 Statin Concomitant: 7\n- Site 02 Enrolled: 16\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 5\n- Site 03 Enrolled: 20\n- Site 03 Active: 20\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 14\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 18\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 4\n- Site 06 Enrolled: 12\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 24\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 6\n- Site 08 Enrolled: 16\n- Site 08 Active: 16\n- Site 08 Statin Concomitant: 5\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 14\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 20\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 16\n- Site 12 Active: 16\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 54\n- ALT (U/L) Mean: 103.2\n- ALT (U/L) Median: 102.1\n- AST (U/L) Mean: 82.6\n- AST (U/L) Median: 81.2\n- Bilirubin (mg/dL) Mean: 1.87\n- Bilirubin (mg/dL) Median: 1.85\n- ALP (U/L) Mean: 79.2\n- ALP (U/L) Median: 55.7\n- Creatinine (mg/dL) Mean: 0.99\n- Creatinine (mg/dL) Median: 1.0\n- BUN (mg/dL) Mean: 16.9\n- BUN (mg/dL) Median: 12.8\n- WBC (K) Mean: 6.2\n- WBC (K) Median: 6.1\n- Platelets (K) Mean: 219\n- Platelets (K) Median: 257\n\n#### Non-Statin Subgroup\n- N: 123\n- ALT (U/L) Mean: 21.8\n- ALT (U/L) Median: 20.2\n- AST (U/L) Mean: 18.5\n- AST (U/L) Median: 16.6\n- Bilirubin (mg/dL) Mean: 0.67\n- Bilirubin (mg/dL) Median: 0.66\n- ALP (U/L) Mean: 64.9\n- ALP (U/L) Median: 53.5\n- Creatinine (mg/dL) Mean: 1.03\n- Creatinine (mg/dL) Median: 0.97\n- BUN (mg/dL) Mean: 13.2\n- BUN (mg/dL) Median: 12.7\n- WBC (K) Mean: 8.5\n- WBC (K) Median: 7.6\n- Platelets (K) Mean: 257\n- Platelets (K) Median: 227\n\n### Adverse Events\n- AE ID: AE-0075, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0076, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0077, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0078, Description: hepatic enzyme measurement out of range, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0079, Description: Hy's Law case: ALT 3.8x ULN, total bilirubin 2.3x ULN, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 55\n- ACE Inhibitor Count: 28\n- Metformin Count: 21\n- PPI Count: 17\n- NSAID Count: 12\n- Other Count: 33\n\n### Protocol Deviations\n- PD ID: PD-042, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_07\n- PD ID: PD-043, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_06\n\n### Investigator Notes\n- Central lab results received within 48h turnaround\n- Lab kits inventory adequate for next 4 weeks\n- SAE report filed: subject 03-042, statin subgroup, ALT 3.8x ULN with bilirubin 2.3x ULN\n- Pharmacology consult requested: CYP3A4 inhibition profile of LNS-4821 under review\n\n### Events\n- Site 07 monitoring visit completed, 3 findings\n- Bioanalytical lab shipment tracking confirmed for 1 samples\n- Central lab courier pickup schedule adjusted for holiday\n- SAE report submitted to sponsor safety group and regulatory authority\n\n### Notes\n- Week 20: Cross-site statin subgroup hepatic signal confirmed. DDI pharmacology review in progress.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_020",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-07-15T10:00:00",
    "phase": "escalation",
    "signal_density": "high",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}